Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02572349 · ClinicalTrials.gov registry record · Phase 1
Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers
A Phase 1 study, sponsored by Cyclerion Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02572349 is a Phase 1 study that has completed, run by Cyclerion Therapeutics. The registered enrollment target is 24 participants.
The verdict
NCT02572349, a Phase 1 study, has completed, sponsored by Cyclerion Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objectives of the study are to assess the safety and tolerability of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects, to determine the pharmacokinetic profile and pharmacodynamics effects of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects.
Interventions
- DRUG Matching Placebo
- DRUG IW-1701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-10 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02572349
The ClinicalTrials.gov registry entry for NCT02572349 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclerion Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT02572349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02572349 about?
NCT02572349 is a clinical study titled "Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers". The objectives of the study are to assess the safety and tolerability of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects, to determine the pharmacokinetic profile and pharmacodynamics effects of a range of single doses of IW-1701 when administered as oral ca...
What is the current status of trial NCT02572349?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-10. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02572349?
The interventions under investigation include: Matching Placebo (DRUG), IW-1701 (DRUG).
Who is sponsoring clinical trial NCT02572349?
This trial is sponsored by Cyclerion Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.